METHOD FOR DETERMINING INDICATIONS IN FAVOR OF CHEMOTHERAPY APPLICATION TO PATIENTS SUFFERING FROM PRIMARY LYMPHOGRANULOMATOSIS AND GENERALIZED MAMMARY GLAND CARCINOMA Russian patent published in 2003 - IPC

FIELD: medicine. SUBSTANCE: method involves determining patient blood neutrophil number. The value being equal to 1.8 to 10,0×10^9/l/l, peripheral blood leukocytes are to be studied after exposing them to gamma- radiation at a dose of 2 Gr. Samples exposed and unexposed to radiation treatment are incubated for 3 days at 37 C and leukocyte DNA concentration is determined therein. Sensitivity index (S) is calculated as ratio of leukocyte DNA concentration in untreated sample to leukocyte DNA concentration in treated one. Neutrophil number being within the limits of 1,8-10,0×10^9/l/l and S index being less than 1.0, combined BEACOPP treatment formula including Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristin, Procarbosin and Prednisolon is considered to be indicated for generalized lymphogranulomatosis patients. The value being below 0.8, combined CMF chemotherapy standard course including Cyclophosphane, Metotrexate, and 5-fluorouracyl is considered to be indicated for generalized mammary gland carcinoma patients. The value being greater than 0.8, combined FAC chemotherapy course including 5-fluorouracyl, Doxorubicin, and Cyclophosphane is considered to be indicated for generalized mammary gland carcinoma patients. EFFECT: enhanced effectiveness of treatment. 3 dwg, 6 tbl